Physician profile
David Montgomery
NPI 1992790935
$790.14
in general payments reported to CMS, 2019-2025
24 companies · $98.03 in 2025
The $98.03 reported for 2025 was less than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $108 · 2020: $110 · 2021: $126 · 2022: $65.64 · 2023: $211 · 2024: $72.21 · 2025: $98.03.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $381.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $380.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $126.82 | 2021-2023 | Gore Synecor Biomaterial |
| Abbvie INC. | $69.02 | 2023 | |
| Davol INC. | $63.60 | 2020-2022 | |
| Portola Pharmaceuticals, LLC | $49.00 | 2019-2020 | |
| Myriad Genetic Laboratories, INC. | $46.27 | 2021-2023 | Myrisk |
| Heron Therapeutics, INC. | $40.39 | 2024-2025 | Zynrelef |
| Baxter Healthcare | $35.88 | 2023 | Tisseel |
| Smith+Nephew, INC. | $32.05 | 2024 | Collagenase Santyl, Iodosorb Ointment 40g USA, Regranex |
| Sirius Medical Systems | $31.71 | 2023 | Pintuition |
| Vertex Pharmaceuticals Incorporated | $29.94 | 2025 | |
| Covidien LP | $28.10 | 2019 | |
| Intuitive Surgical, INC. | $25.90 | 2020 | |
| Eagle Pharmaceuticals, INC. | $25.00 | 2023 | |
| Organogenesis INC. | $20.69 | 2024 | Puraply Franchise |
| Medtronic, INC. | $19.07 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Endomagnetics LTD | $18.35 | 2021 | |
| Ethicon US, LLC | $18.31 | 2020 | |
| Csl Behring | $17.89 | 2019 | |
| Pacira Pharmaceuticals Incorporated | $16.37 | 2025 | Exparel |
| Reprise Biomedical, INC. | $16.21 | 2025 | Miro3d |
| Medtronic USA, INC. | $15.53 | 2019 | |
| Allergan, INC. | $15.50 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $14.59 | 2025 | Farxiga |
| Merck Sharp & Dohme LLC | $13.95 | 2023 | Bridion |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Montgomery listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.